Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) released its earnings results on Thursday. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12), Zacks reports. The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock traded up $0.25 during midday trading on Friday, reaching $30.50. The stock had a trading volume of 762,752 shares, compared to its average volume of 531,667. The stock has a market capitalization of $1.98 billion, a P/E ratio of -12.98 and a beta of 2.18. The firm’s fifty day simple moving average is $39.21 and its 200-day simple moving average is $43.82. Kymera Therapeutics has a 1-year low of $29.16 and a 1-year high of $53.27.

Insider Activity

In related news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.82% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KYMR. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. BMO Capital Markets initiated coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 price target for the company. UBS Group decreased their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday, November 4th. Morgan Stanley upped their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright lifted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.